Krystal Biotech (KRYS) Net Cash Flow (2016 - 2026)

Krystal Biotech's Net Cash Flow history runs 11 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 117.48% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $193.8 million (up 489.37% YoY), while the FY2025 annual figure was $151.2 million, up 1262.27% from the prior year.
• Net Cash Flow came in at $6.3 million for Q1 2026 at Krystal Biotech, down from $104.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $135.1 million in Q2 2023 to a low of -$71.9 million in Q1 2022.
• A 5-year average of $9.5 million and a median of -$12.9 million in 2024 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 466.0% in 2025 and fell as far as 7486.15% in 2025.
• Krystal Biotech's Net Cash Flow stood at -$24.5 million in 2022, then jumped by 39.62% to -$14.8 million in 2023, then sank by 92.97% to -$28.5 million in 2024, then surged by 466.0% to $104.3 million in 2025, then sank by 93.92% to $6.3 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $6.3 million, $104.3 million, and $39.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison